What Options Are Available for Refractory Pancreatic Cancer?

  • Minsig Choi Department of Oncology, Karmanos Cancer Institute, Wayne State University. Detroit, MI, USA.
  • Richard Kim Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center. Tampa, FL, USA
  • Muhammad Wasif Saif Division of Hematology and Oncology and Section of GI Cancers, Columbia University College of Physicians and Surgeons. New York, NY, USA
DOI: https://doi.org/10.6092/1590-8577/720
Keywords: FOLFIRINOX, 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin, OFF, oxaliplatin, and 5-fluorouracil, SPARC, secreted protein acidic and rich in cysteine, XELOX, capecitabine and oxaliplatin

Abstract

 

Currently gemcitabine-based regimens and FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) are widely used standard for first-line treatment of patients with advanced pancreatic adenocarcinoma. Refractory patients may receive either FOLFOX (5-fluorouracil and oxaliplatin) or gemcitabine based on the first line regimen. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #248 and #373 of the meeting.

 

Downloads

Download data is not yet available.

Author Biography

Minsig Choi, Department of Oncology, Karmanos Cancer Institute, Wayne State University. Detroit, MI, USA.
assistant professor of oncology

References

Burris HA, III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.

Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: 4010

T Conroy, F Desseigne and M Ychou et al., Randomized phase III trial comparing FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817.

Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26(15 Suppl):4508.

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et. al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676.

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-52.

Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; 16:539.

Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel asweekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635-638.

Hosein PJ, Pastorini VH, Gomez CM, Macintyre J, Merchan JR,Ferrell A, et al. A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine-based therapy. J Clin Oncol 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 214.

Ernani V, Akunyili II, Hosein PJ, Macintyre J, Rocha Lima CM. Gemcitabine (G) and nab-paclitaxel (nab-P) in patients with refractory advanced pancreatic cancer (PC). J Clin Oncol 30, 2012 (suppl 4; abstr 373)

Fukahori M. Efficacy of gemcitabine as second-line therapy after S-1 therapy failure in advanced pancreatic carcinoma. J Clin Oncol 30, 2012 (suppl 4; abstr 248)

Awasthi N, Ostapoff K, Zhang C, Schwarz MA, Schwarz R. Evaluation of combination treatment benefits of nab-paclitaxel in experimental pancreatic cancer . J Clin Oncol 30, 2012 (suppl 4; abstr 170)

Nakamori S, Tsujie M, Miyamoto A, Kurokawa Y, Yasui M, Ikenaga M, et al. Impact of the combination of S-1 administration prior to gemcitabine as a second-line therapy for unresectable/recurrent pancreatic cancer. J Clin Oncol 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 241.

Department of Oncology, Karmanos Cancer Institute, Wayne State University. Detroit, MI, USA
Published
2012-03-10
How to Cite
ChoiM., KimR., & SaifM. (2012). What Options Are Available for Refractory Pancreatic Cancer?. JOP. Journal of the Pancreas, 13(2), 163-165. https://doi.org/10.6092/1590-8577/720
Issue
Vol 13 No 2 (2012): March - p. 124-251
Section
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012

Copyright (c) 2014 Minsig Choi, Richard Kim, Muhammad Wasif Saif

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.